Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, Fava C, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G. Latagliata R, et al. Among authors: rizzo m. Neoplasia. 2016 Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005. Neoplasia. 2016. PMID: 27659013 Free PMC article.
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F. Cicconi L, et al. Among authors: rizzo m. Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27. Ann Hematol. 2018. PMID: 29951912
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
Santoleri F, Ranucci E, La Barba G, Colasanto I, Scaldaferri M, Cattel F, Federici F, Rossi C, Di Biagio K, Scortechini AR, Musicco F, Torquati G, Frazzetto A, Vozza A, de Rosa C, Lanzillo R, Monteverde M, Luciano L, Pane F, Pasquazi A, Celeste MG, Cantonetti M, Franceschini L, Rizzo M, Costantini A. Santoleri F, et al. Among authors: rizzo m. Curr Med Res Opin. 2021 Mar;37(3):477-481. doi: 10.1080/03007995.2021.1876006. Epub 2021 Jan 29. Curr Med Res Opin. 2021. PMID: 33459083
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A. Maurillo L, et al. Among authors: rizzo m. J Clin Oncol. 2008 Oct 20;26(30):4944-51. doi: 10.1200/JCO.2007.15.9814. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606980 Free article.
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia.
Gurnari C, Panetta P, Fabiani E, Nardone AM, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda VM, De Bellis E, Lo-Coco F, Voso MT. Gurnari C, et al. Among authors: rizzo m. Mol Clin Oncol. 2018 Mar;8(3):463-465. doi: 10.3892/mco.2017.1543. Epub 2017 Dec 29. Mol Clin Oncol. 2018. PMID: 29468060 Free PMC article.
New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia.
Ianniello Z, Sorci M, Ceci Ginistrelli L, Iaiza A, Marchioni M, Tito C, Capuano E, Masciarelli S, Ottone T, Attrotto C, Rizzo M, Franceschini L, de Pretis S, Voso MT, Pelizzola M, Fazi F, Fatica A. Ianniello Z, et al. Among authors: rizzo m. Cell Death Dis. 2021 Sep 24;12(10):870. doi: 10.1038/s41419-021-04169-7. Cell Death Dis. 2021. PMID: 34561421 Free PMC article.
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M. Palumbo A, et al. Among authors: rizzo m. Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1. Blood. 2010. PMID: 19965659 Free article. Clinical Trial.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: rizzo m. J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12. J Clin Oncol. 2010. PMID: 20940200 Clinical Trial.
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. Martelli M, et al. Among authors: rizzo m. J Clin Oncol. 2003 Apr 1;21(7):1255-62. doi: 10.1200/JCO.2003.01.117. J Clin Oncol. 2003. PMID: 12663712 Clinical Trial.
2,306 results